Biopharma Co. Maxygen Fears Amgen Might Sue

Law360, New York (June 13, 2008, 12:00 AM EDT) -- Biopharmaceutical company Maxygen Inc. has warned that Amgen Inc. might look to file a patent infringement suit against the company when it starts seeking regulatory approval for MAXY-G34, its treatment for the blood deficiency neutropenia.

In a regulatory document filed with the U.S. Securities and Exchange Commission on Thursday, Maxygen revealed that Amgen may claim that its recently issued patent describing certain granulocyte colony-stimulating factor hybrid molecules is infringed by Maxygen’s G-CSF program, MAXY-G34.

MAXY-G34, which is covered by several patents and patents pending owned by...
To view the full article, register now.